M A Pruis1, W R R Geurts-Giele2, Thüsen J H von der2, I C Meijssen2, W N M Dinjens2, J G J V Aerts3, A M C Dingemans4, M P Lolkema5, M S Paats3, H J Dubbink6. 1. Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. 2. Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. 3. Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. 4. Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Pulmonary Diseases, Maastricht UMC +, Maastricht, the Netherlands. 5. Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. 6. Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: h.dubbink@erasmusmc.nl.
Abstract
OBJECTIVES: The oncogenic MET exon 14 skipping mutation (METex14del) is described to drive 1.3 %-5.7 % of non-small-cell lung cancer (NSCLC) and multiple studies with cMET inhibitors show promising clinical responses. RNA-based analysis seems most optimal for METex14del detection, however, acquiring sufficient RNA material is often problematic. An alternative is DNA-based analysis, but commercially available DNA-based panels only detect up to 63 % of known METex14del alterations. The goal of this study is to describe an optimized DNA-based diagnostic test for METex14del in NSCLC, including clinical features and follow-up of patients treated with cMET-targeted therapy and consequent resistance mechanisms. MATERIAL AND METHODS: Routinely processed diagnostic pathology non-squamous NSCLC specimens were investigated by a custom-made DNA-based targeted amplicon-based next generation sequencing (NGS) panel, which includes 4 amplicons for METex14del detection. Retrospectively, histopathological characteristics and clinical follow up were investigated for advanced non-squamous NSCLC with METex14del. RESULTS: In silico analysis showed that our NGS panel is able to detect 96 % of reported METex14 alterations. METex14del was found in 2 % of patients with non-squamous NSCLC tested for therapeutic purposes. In total, from May 2015 - Sep 2018, METex14del was found in 46 patients. Thirty-six of these patients had advanced non-squamous NSCLC, they were predominantly elderly (76.5 years [53-90]), male (25/36) and (ex)-smokers (23/36). Five patients received treatment with crizotinib (Pfizer Oncology), in a named patient based program, disease control was achieved for 4/5 patients (3 partial responses, 1 stable disease) and one patient had a mixed response. Two patients developed a MET D1228N mutation during crizotinib treatment, inducing a resistance mechanism to crizotinib. CONCLUSIONS: This study shows that METex14del can be reliably detected by routine DNA NGS analysis. Although a small cohort, patients responded well to targeted treatment, underlining the need for routine testing of METex14del in advanced non-squamous NSCLC to guarantee optimal personalized treatment.
OBJECTIVES: The oncogenic MET exon 14 skipping mutation (METex14del) is described to drive 1.3 %-5.7 % of non-small-cell lung cancer (NSCLC) and multiple studies with cMET inhibitors show promising clinical responses. RNA-based analysis seems most optimal for METex14del detection, however, acquiring sufficient RNA material is often problematic. An alternative is DNA-based analysis, but commercially available DNA-based panels only detect up to 63 % of known METex14del alterations. The goal of this study is to describe an optimized DNA-based diagnostic test for METex14del in NSCLC, including clinical features and follow-up of patients treated with cMET-targeted therapy and consequent resistance mechanisms. MATERIAL AND METHODS: Routinely processed diagnostic pathology non-squamous NSCLC specimens were investigated by a custom-made DNA-based targeted amplicon-based next generation sequencing (NGS) panel, which includes 4 amplicons for METex14del detection. Retrospectively, histopathological characteristics and clinical follow up were investigated for advanced non-squamous NSCLC with METex14del. RESULTS: In silico analysis showed that our NGS panel is able to detect 96 % of reported METex14 alterations. METex14del was found in 2 % of patients with non-squamous NSCLC tested for therapeutic purposes. In total, from May 2015 - Sep 2018, METex14del was found in 46 patients. Thirty-six of these patients had advanced non-squamous NSCLC, they were predominantly elderly (76.5 years [53-90]), male (25/36) and (ex)-smokers (23/36). Five patients received treatment with crizotinib (Pfizer Oncology), in a named patient based program, disease control was achieved for 4/5 patients (3 partial responses, 1 stable disease) and one patient had a mixed response. Two patients developed a MET D1228N mutation during crizotinib treatment, inducing a resistance mechanism to crizotinib. CONCLUSIONS: This study shows that METex14del can be reliably detected by routine DNA NGS analysis. Although a small cohort, patients responded well to targeted treatment, underlining the need for routine testing of METex14del in advanced non-squamous NSCLC to guarantee optimal personalized treatment.
Authors: Vladimir Nosi; Alessandrì Luca; Melissa Milan; Maddalena Arigoni; Silvia Benvenuti; Davide Cacchiarelli; Marcella Cesana; Sara Riccardo; Lucio Di Filippo; Francesca Cordero; Marco Beccuti; Paolo M Comoglio; Raffaele A Calogero Journal: Int J Mol Sci Date: 2021-04-19 Impact factor: 5.923
Authors: Mark Pieterse; Joost Swennenhuis; G Tjitske Los-de Vries; Amin Allahyar; Mehmet Yilmaz; Roos Leguit; Ruud W J Meijers; Robert van der Geize; Joost Vermaat; Arjen Cleven; Tom van Wezel; Arjan Diepstra; Léon C van Kempen; Nathalie J Hijmering; Phylicia Stathi; Milan Sharma; Adrien S J Melquiond; Paula J P de Vree; Marjon J A M Verstegen; Peter H L Krijger; Karima Hajo; Marieke Simonis; Agata Rakszewska; Max van Min; Daphne de Jong; Bauke Ylstra; Harma Feitsma; Erik Splinter; Wouter de Laat Journal: Nat Commun Date: 2021-06-07 Impact factor: 14.919
Authors: Bart Koopman; Birgitta I Hiddinga; Inge Platteel; Joost L Kluiver; Wim Timens; André B Mulder; Jaap A van Doesum; Ed Schuuring; Arjan Diepstra; Léon C van Kempen Journal: Histopathology Date: 2021-04-03 Impact factor: 7.778
Authors: Thomas van Doeveren; Jose A Nakauma-Gonzalez; Andrew S Mason; Geert J L H van Leenders; Tahlita C M Zuiverloon; Ellen C Zwarthoff; Isabelle C Meijssen; Angelique C van der Made; Antoine G van der Heijden; Kees Hendricksen; Bas W G van Rhijn; Charlotte S Voskuilen; Job van Riet; Winand N M Dinjens; Hendrikus J Dubbink; Harmen J G van de Werken; Joost L Boormans Journal: Int J Cancer Date: 2020-10-13 Impact factor: 7.396